The 2022 Tandem Meetings | Cord blood transplantation vs MMUD with PTCy in AML
Bhagirathbhai Dholaria, MBBS, Vanderbilt University Medical Center, Nashville, TN, discusses the finding of a study comparing cord blood transplantation versus mismatched unrelated donor (MMUD) with post-transplant cyclophosphamide (PTCy) in patients with acute myeloid leukemia (AML). The study found that there was a higher rate of non-relapse mortality (NRM) and graft failure in cord blood transplant recipients compared to MMUD recipients. In addition, the study found that the risk of graft-versus-host disease (GvHD) was lower in MMUD recipients treated with PTCy. Overall, this study strongly supports the use of MMUD transplantation. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
